The therapeutic potential of transferring HBV immunity initially emerged through clinical reports of CHB patients who cleared the infection after receiving a bone marrow transplant from HBV-immune donors, giving rise to HBV-specific CD4+ and CD8+ T cells as well as B cells.4 Here, CD4 is linked to infection.